Login / Signup

In vitro isavuconazole activity against Sporothrix brasiliensis suggests its efficacy in some severe sporotrichosis cases.

Fernando Almeida-SilvaRowena Alves CoelhoAndréa Reis Bernardes-EngemannVivian FichmanDayvison Francis Saraiva FreitasMaria Clara Gutierrez-GalhardoDario Corrêa-JuniorSusana FrasesRosely Maria Zancopé-OliveiraRodrigo Almeida-Paes
Published in: Future microbiology (2023)
Background: Sporothrix brasiliensis causes sporotrichosis, an important infection in some groups of patients. Aims: This work was designed to investigate the effects of isavuconazole against this species. Methods: An antifungal susceptibility test was performed to compare MIC values with other antifungal drugs used to treat sporotrichosis. A checkerboard assay was performed to understand isavuconazole interactions. Furthermore, isavuconazole growth inhibition on an itraconazole-resistant strain was tested. Results: Isavuconazole had similar MICs to other azoles against S. brasiliensis , presenting fungistatic activity. Isavuconazole did not interact in vitro with antifungals or immunosuppressive drugs and inhibited the growth of an itraconazole-resistant strain. Conclusion: Isavuconazole inhibits S. brasiliensis , its pharmacologic characteristics make it a candidate for patients with sporotrichosis and it may be useful to combat sporotrichosis caused by resistant isolates.
Keyphrases
  • end stage renal disease
  • candida albicans
  • newly diagnosed
  • peritoneal dialysis
  • prognostic factors
  • case report
  • patient reported outcomes